Promising findings of glucagon-like peptide-1 receptor agonists, such as semaglutide and beinaglutide [9,10], have spurred many individuals living with obesity to adopt new pharmacotherapies, leading this group to increasingly access OMC to get prescriptions for weight-loss drugs. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.